As per the agreement, Altea and KAI are expected to examine the transdermal delivery of certain Kai proprietary compounds using Altea’s transdermal delivery technology, the PassPort System.
Moreover, Altea has granted KAI an option to receive a worldwide technology license for the further development and commercialization of these novel transdermal products. Should KAI exercise the option, it will fund all product development, manufacturing and commercialisation activities, and Altea may receive license payments, development and commercialization milestones and royalties on product sales from KAI.
Eric Tomlinson, president and CEO of Altea Therapeutics, said: “We are pleased to enter into this agreement with Kai. The agreement further validates the broad application of the Altea Therapeutics novel transdermal patch technology for the transdermal delivery of water-soluble compounds.
“While we continue to apply our transdermal technology to currently approved drugs that previously were administered by needle injection or infusion, including water-soluble proteins, carbohydrates and small molecules, this new partnership allows us to apply our technology to the new peptide drugs being developed by KAI Pharmaceuticals.”